Citations

Mayo Clinic

Showing 10 of 108599 citations.

Holmium Laser Enucleation of the Prostate After Prostatic Urethral Lift Surgery: Feasibility and Technical Considerations from a Multi-Institutional Case Series
McAdams, Sean , Funk, Joel, Navetta, Andrew , Tayeb, Marawan M. El , Humphreys, Mitchell R.

Journal of Endourology | June 6, 2017 | Volume: 31 | Issue: 8 | Pages: 774-779

10.1089/end.2017.0224 | PMID 28586247 Get It

A Lipidomics Approach to Assess the Association Between Plasma Sphingolipids and Verbal Memory Performance in Coronary Artery Disease Patients Undertaking Cardiac Rehabilitation: A C18:0 Signature for Cognitive Response to Exercise
Saleem, Mahwesh, Herrmann, Nathan , Dinoff, Adam, Mielke, Michelle M. , Oh, Paul , Shammi, Prathiba , Cao, Xingshan , Venkata, Swarajya Lakshmi Vattem, Haughey, Norman J. , Lanctôt, Krista L. , Mielke, Michelle M

Journal of Alzheimer's Disease | June 6, 2017 | Volume: 60 | Issue: 3 | Pages: 829-841

10.3233/jad-161292 | PMID 28598843 Get It

Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer
Radisky, Evette S. , Raeeszadeh‐Sarmazdeh, Maryam , Radisky, Derek C. , Radisky, Evette S

Journal of Cellular Biochemistry | June 6, 2017 | Volume: 118 | Issue: 11 | Pages: 3531-3548

10.1002/jcb.26185 | PMID 28585723 Get It

ABSTRACTMatrix metalloproteinases (MMPs) are a family of zinc endopeptidases that cleave nearly all components of the extracellular matrix as well as many other soluble and cell‐associated proteins. MMPs have been implicated in normal physiological processes, including development, and in the acquisition and progression of the malignant phenotype. Disappointing results from a series of clinical trials testing small molecule, broad spectrum MMP inhibitors as cancer therapeutics led to a re‐evaluation of how MMPs function in the tumor microenvironment, and ongoing research continues to reveal that these proteins play complex roles in cancer development and progression. It is now clear that effective targeting of MMPs for therapeutic benefit will require selective inhibition of specific MMPs. Here, we provide an overview of the MMP family and its biological regulators, the tissue inhibitors of metalloproteinases (TIMPs). We then summarize recent research from model systems that elucidate how specific MMPs drive the malignant phenotype of breast cancer cells, including acquisition of cancer stem cell features and induction of the epithelial–mesenchymal transition, and we also outline clinical studies that implicate specific MMPs in breast cancer outcomes. We conclude by discussing ongoing strategies for development of inhibitors with therapeutic potential that are capable of selectively targeting the MMPs most responsible for tumor promotion, with special consideration of the potential of biologics including antibodies and engineered proteins based on the TIMP scaffold. J. Cell. Biochem. 118: 3531–3548, 2017. © 2017 The Authors. Journal of Cellular Biochemistry Published by Wiley Periodicals, Inc.
Faculty Opinions recommendation of ATP as a biological hydrotrope.
Maher, Jim

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | June 6, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.727620650.793532706 Get It

Cholesterol uptake and regulation in high-grade and lethal prostate cancers
Stopsack, Konrad H. , Gerke, Travis , Andrén, Ove, Andersson, Swen‐Olof, Giovannucci, Edward L. , Mucci, Lorelei A. , Rider, Jennifer R. , Gerke, Travis A, Stopsack, Konrad H

Carcinogenesis | June 6, 2017 | Volume: 38 | Issue: 8 | Pages: 806-811

10.1093/carcin/bgx058 | PMID 28595267 Get It

Tympanostomy Tube Placement in Children Using a Single‐Pass Tool with Moderate Sedation
Cofer, Shelagh A. , Meyer, Abby, Yoon, Daniel, Beebe, David S., Castro, Chandra, Rimell, Frank L., Belani, Kumar G. , Cofer, Shelagh, Meyer, Abby C.

Otolaryngology–Head and Neck Surgery | June 6, 2017 | Volume: 157 | Issue: 3 | Pages: 533-535

10.1177/0194599817707178 | PMID 28585495 Get It

Insertion of tympanostomy tubes is a common elective pediatric surgical procedure and is typically performed under general anesthesia. The potential to reduce general anesthetic requirements for young children has led to increased interest in alternatives for tympanostomy tube placement. A tympanostomy tube system, developed to enable tympanostomy tube placement in a single pass on conscious patients under moderate sedation, was evaluated. A prospective study on 128 children and 253 tympanostomy tube placements conducted at 4 centers in the United States demonstrated an 88.3% success rate in performing the procedure under moderate sedation with adverse events within normal rates reported in the literature. The feasibility of completing tympanostomy tube placement under moderate sedation enables avoidance of general anesthesia and provides additional choices to physicians and parents.
“It’s important, but…”: Perceived Barriers and Situational Dependencies to Social Contact Preferences of Nursing Home Residents
Abbott, Katherine , Bangerter, Lauren R. , Humes, Sarah, Klumpp, Rachel, Haitsma, Kimberly Van, Abbott, Katherine M

The Gerontologist | June 6, 2017 | Volume: 58 | Issue: 6 | Pages: 1126-1135

10.1093/geront/gnx109 | PMID 28645167 Get It

Pilot report: non-operative treatment of Mayo Type II olecranon fractures in any-age adult patient
Putnam, Matthew D. , Christophersen, Christy, Adams, Julie E. , Adams, Julie , Adams, Julie E

Shoulder & Elbow | June 6, 2017 | Volume: 9 | Issue: 4 | Pages: 285-291

10.1177/1758573217711889 | PMID 28932286 Get It

Background We report on the non-operative treatment of Mayo Type II olecranon fractures. Methods Fourteen isolated Mayo Type II olecranon fractures were treated non-operatively, followed to discharge, and retrospectively reviewed. Treatment was splinting in extension followed by protected active motion beginning 3 weeks to 4 weeks post-injury. Mayo Elbow Performance Index (MEPI) and Shortened Disabilities of the Arm, Shoulder and Hand (QuickDASH) scores were available in 86% and 64% of cases, respectively. Follow-up radiographs were obtained. Results At discharge, the mean (SD) MEPI score was 95 (5). The mean (SD) elbow motion arc was 121° (21°). One patient re-fractured his elbow after discharge by falling on the ice. He recovered after open reduction and internal fixation. One patient (documented Marfan syndrome) developed an asymptomatic non-union. Excepting the patient who fell, no patient received additional care. Conclusions In this pilot report, Mayo Type II olecranon fractures were treated non-operatively to discharge. Good to excellent results were obtained in all patients according to the MEPI. Supportive care of these fractures should be comparatively studied. A downside risk to providing supportive care for these fractures was not identified.
Comparison of Levetiracetam Dosing Regimens in End-Stage Renal Disease Patients Undergoing Intermittent Hemodialysis
Shiue, Harn , Taylor, Maria E., Sands, Kara, Shiue, Harn J, Sands, Kara A, Shiue, Harn J

Annals of Pharmacotherapy | June 6, 2017 | Volume: 51 | Issue: 10 | Pages: 862-865

10.1177/1060028017713294 | PMID 28582998 Get It

Background: Levetiracetam (LEV) is primarily renally eliminated. In end-stage renal disease (ESRD) patients on hemodialysis (HD), pharmacokinetic studies recommend daily dosing with 50% supplemental doses after 4-hour HD sessions. However, poor medication adherence after HD could result in fluctuating plasma drug levels. Objective: To compare two LEV dosing regimens, daily versus twice-daily (BID), in ESRD patients undergoing HD. Methods: Consecutive ESRD patients (April 2013 to May 2014) receiving maintenance inpatient HD and prescribed LEV prior to admission to our academic tertiary hospital were prospectively analyzed. Demographics, initial lab values, adverse reactions, seizures, and LEV regimens were recorded. LEV levels were obtained pre-HD and post-HD along with levels after receiving post-HD doses. Recovery of plasma levels after HD was assessed by comparison of levels predialysis versus postdialysis and post-HD doses. Results: We identified 22 patients who met inclusion criteria; 14 BID and 8 daily dosing. Mean predialysis, postdialysis, and post-HD dose plasma levels were higher in patients receiving LEV BID compared with daily (43.1 ± 6.3, 19.4 ± 5.2, 34.9 ± 4.3 vs 21.1 ± 3.9, 6.9 ± 1.5, 11.9 ± 1.7 µg/mL; P < 0.05). BID post-HD levels were 41.9 ± 4.6% of predialysis levels versus 36.9 ± 7.3% with daily dosing ( P = 0.275). Post-HD dose levels were 81.4±4.3% of predialysis on LEV BID versus 65.7 ± 8.8% on LEV daily ( P = 0.045). No seizures were reported during hospital admission in either group. Conclusions: Compared to LEV daily, BID dosing achieved significantly higher levels and a better recovery to predialysis levels. Although limited by small numbers, a similar relationship between postdialysis levels was not detected.
Neurons Over Nephrons
Brinjikji, Waleed , Demchuk, Andrew M. , Murad, M. Hassan , McDonald, Robert J. , Kallmes, David F. , Murad, Mohammad H, Rabinstein, Alejandro A. , McDonald, Jennifer S. , Murad, M Hassan , Demchuk, Andrew M

Stroke | June 6, 2017 | Volume: 48 | Issue: 7 | Pages: 1862-1868

10.1161/strokeaha.117.016771 | PMID 28583996 Get It

Background and Purpose— Because of the perceived risk of contrast-induced acute kidney injury (AKI), many centers require pre-imaging serum creatinine levels, potentially delaying care. We performed a systematic review and meta-analysis evaluating AKI rates in patients with acute ischemic stroke receiving computed tomographic angiography (CTA) and computed tomographic perfusion (CTP). Methods— We searched MEDLINE, EMBASE, and the Web of Science through December 2016 for studies reporting on AKI in patients with acute ischemic stroke receiving CTA/CTP. Using a random-effects model, estimates were pooled across studies. Outcomes of interest were (1) the odds of AKI in patients receiving CTA/CTP versus noncontrast computed tomography, (2) overall rate of AKI and hemodialysis in patients with acute ischemic stroke undergoing CTA/CTP, and (3) the odds of CTA/CTP-associated AKI among patients with and without chronic kidney disease. Results— Fourteen studies were included (6 case–control studies and 8 single-arm studies) with 5727 CTA/CTP and 981 noncontrast computed tomography patients. In case–control studies, AKI was significantly lower among CTA/CTP patients compared with noncontrast computed tomography patients (odds ratio=0.47; 95% confidence interval=0.33–0.68; P <0.01). Adjusting for baseline creatinine, there was no difference in AKI rates between groups (odds ratio=0.34; 95% confidence interval=0.10–1.21). The overall rate of AKI in CTA/CTP patients was 3% (95% confidence interval=2%–4%). The overall rate of hemodialysis in the CTA/CTP group was 0.07% (3 of 4373). There was no difference in AKI among CTA/CTP patients with and without chronic kidney disease (odds ratio=0.63; 95% confidence interval=0.34–1.12). Conclusions— Nonrandomized evidence suggests that CTA/CTP are not associated with statistically significant increase in risk of AKI in patients with stroke, even those with known chronic kidney disease.